【摘要】  目的：探询与糖尿病视网膜病变发生发展相关的可定量血液检测指标，以便对发生增殖性糖尿病视网膜病变的高危患者进行监测，为适时的预防性激光光凝治疗提供依据。方法：抽取无增殖期糖尿病视网膜病变的糖尿病患者、增殖期糖尿病视网膜病变患者及无糖尿患者群静脉血，检测糖化血红蛋白（HbA1c）、血清C反应蛋白（CRP）及血管粘附因子（sICAM-1）水平，比较各组之间统计学差异。 结果：HbA1c水平在正常对照与糖尿病患者之间有显著性差异，在无增殖期糖尿病视网膜病变的糖尿病患者组与增殖期糖尿病视网膜病变患者组之间无显著性差异，正常对照分别与另两组比较均有显著性差异。CRP水平在增殖期糖尿病视网膜病变患者组与另两组均有统计学差异。sICAM-1水平各组比较无显著性统计学意义。结论：血HbA1c和CRP水平可能对糖尿病视网膜病变发生和发展有提示意义。

  【关键词】  糖尿病视网膜病变；血管粘附因子；C反应蛋白；糖化血红蛋白

    Analysis of the correlation between diabetic retinopathy and related serum levels

    Jing Zhao, Hong Dai

    Department of Ophthalmology, Beijing Hospital, Beijing 100730, China

    Abstract AIM: To investigate some quantitative serum factors related to diabetic retinopathy so as to inspect the high risk of proliferative diabetic retinopathy and to carry out retinal photocoagulation therapy in time. METHODS: The serum levels of hemoglobin A1c (HbA1c), C-reactive protein (CRP) and intercellular adhesion molecule-1 (sICAM-1) were measured respectively in diabetics patients with and without proliferative diabetic retinopathy as well as normal people. The data were analyzed between the three groups. RESULTS: The level of HbA1c in normal group were significantly lower than that in diabetics groups (P＜0.005), but there was no significant difference between the diabetic groups with and without proliferative diabetic retinopathy. The level of CRP in proliferative diabetic retinopathy patients were significantly higher than the other two groups (P＜0.01). There was no significant difference on the level of sICAM-1 between the three groups. CONCLUSION: The level of HbA1c and CRP may play important roles in reflecting the progress of diabetic retinopathy.

    · KEYWORDS: diabetic retinopathy; intercellular adhesion molecule-1; C-reactive protein; hemoglobin A1c

    0引言

    随着生活水平的提高和饮食结构的改变，糖尿病的发病率逐渐增长，其中2型糖尿病占据着主要比例。糖尿病视网膜病变作为糖尿病重大微血管并发症之一，其相对不可逆性及对视功能的严重损害对患者的生活质量造成了极大影响，其发病机制的研究及有效规范治疗方法的探索成为世界内分泌及眼科领域的重要课题。目前，内科病情控制、视网膜病变的早期发现以及适量、适时、及时的视网膜激光光凝治疗是预防和控制糖尿病视网膜病变发展的重要内容。因此，我们希望通过一些可定量的检测指标，反映糖尿病视网膜病变发生发展的危险程度，对随诊频率、预防性治疗力度、时机提供指导。

[1] [2] [3] 下一页